Company news
Wuxi Biologics (cayman) Inc. (HKEX:2269) news
Wuxi Biologics (cayman) Inc. news releases on 6ix. Latest, Aug 25, 2026: WuXi Biologics Reports Strong Profitable Growth in H1 2026
Press releases & updates
WuXi Biologics Reports Strong Profitable Growth in H1 2026
August 25, 2026
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
August 18, 2026
WuXi Biologics Cayman : Announces Divestment of Controlling Stake in Bestchrom
August 13, 2026
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
July 27, 2026
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
July 9, 2026
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
July 8, 2026
WuXi Biologics Cayman : Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
July 7, 2026
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
June 30, 2026
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
June 24, 2026
WuXi Biologics Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
June 19, 2026
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
June 18, 2026
WuXi Biologics Cayman : Included in S&P Global Sustainability Yearbook (China Edition) for Fourth Consecutive Year
June 11, 2026
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
June 8, 2026
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
June 3, 2026
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
June 1, 2026
WuXi Biologics Cayman : Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
June 1, 2026
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
May 27, 2026
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
May 20, 2026
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
May 11, 2026
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
April 29, 2026
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
April 24, 2026
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
April 23, 2026
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
April 17, 2026
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
April 13, 2026
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
March 30, 2026
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
March 25, 2026
WuXi Biologics Reports Record 2025 Annual Results
March 24, 2026
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
March 20, 2026
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
March 11, 2026
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs
March 12, 2026
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
February 28, 2026
WuXi Vaccines Receives Brazil's ANVISA GMP Certification
February 10, 2026
WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
February 7, 2026
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
February 1, 2026
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
January 27, 2026
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
January 26, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
January 26, 2026
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
January 13, 2026
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
January 12, 2026
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
January 11, 2026
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
January 3, 2026
WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
December 22, 2025
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
December 19, 2025
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
December 2, 2025
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 11, 2025
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
October 20, 2025
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
October 20, 2025
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
October 8, 2025
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
September 25, 2025
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
September 25, 2025